newsfilter
← Latest News
Business Wire·

Janux Therapeutics Reports Second Quarter 2023 Financial Results and Business Highlights

Presented positive interim Phase 1 clinical trial data for PSMA-TRACTr JANX007 in prostate cancer Management team bolstered with key appointment $303.3 million in cash, cash equivalents, and short-term